Showing 2791-2800 of 6036 results for "".
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- iCare USA Receives FDA 510(k) Clearance for Eidon Ultra-Widefield Lens Modulehttps://modernod.com/news/icare-usa-presents-ultra-widefield-imaging-for-the-eidon-diagnostics-platform/2480330/iCare USA has received FDA 510 (k) clearance for the Eidon Ultra-Widefield Lens module.&
- CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression After 2 Yearshttps://modernod.com/news/coopervision-sightglass-vision-diffusion-optics-technology-demonstrates-significant-reduction-in-myopia-progression-after-two-years/2480328/CooperVision’s SightGlass Vision Business has revealed 2-year clinical study data for its Diffusion Optics Technology, which is designed to slow the progression of myopia in children.1 After 2 years, children who wore their Diffusion Optics Technology-enabled spectacles full
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat
- TissueTech Hosts Inaugural Leadership Summit to Discuss Best Practices on Regenerative Medicinehttps://modernod.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/TissueTech announced that the company had completed its first physician leadership summit, Beyond the Horizon 2021,
- Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementiahttps://modernod.com/news/comorbid-ophthalmic-systemic-conditions-linked-with-higher-risk-of-dementia/2480281/People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition, according to a report in the American Journal of Managed Care. Some ophthalmic condition
- MeiraGTx Announces Data at EURETINA 2021 Demonstrating Reversal of Disease Progression Following Treatment With AAV5-RPGR in XLRPhttps://modernod.com/news/meiragtx-announces-data-at-euretina-2021-demonstrating-reversal-of-disease-progression-following-treatment-with-aav5-rpgr-in-xlrp/2479499/MeiraGTx Holdings announced new data from subjects treated in the phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal fun
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti 1-Day Lenseshttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-1-day-lenses/2479496/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifical
- Amydis Receives NIH Grant to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and Other Tauopathieshttps://modernod.com/news/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/2479481/Amydis announced a new phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH) to support the development of a novel small-molecule retinal tracer targeting the biomarker tau for the detection and diagnosis of Alzheimer’s disease and other tauopathies.<
- New Virtual Training Takes on Leading Cause of Childhood Blindnesshttps://modernod.com/news/new-virtual-training-takes-on-leading-cause-of-childhood-blindness/2479471/Orbis International, with support from Alcon, launched a new virtual Flying Eye Hospital project that will train eye care professionals across Latin America to treat retinopathy of prematurity (ROP), the leading cause of blindness among children worldwide. Affecti